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Abstract
Polyhydroxyalkanoates (PHAs), a class of biopolyesters produced and stored by
bacteria, have garnered attention for a number of industrial and biomedical
applications. The goal of the current study was to extend the use of PHAs to drug
delivery for the treatment of cancer. As a first step, the cytotoxicity of poly(3hydroxy-octanoate-co-10-undecanoate) (PHOU) towards the A549 lung carcinoma
cell line was determined and nanoparticles were prepared via a single emulsion
technique. Elution tests, whereby cells were grown in fluid extracts obtained from
media incubated for 24 hours at 37°C with PHOU films, did not result in any
significant changes in cellular appearance or proliferation, as determined by
microscopy and a WST-8 cellular proliferation assay. In contrast, direct contact
assays that required growth of the cells on the PHOU films, resulted in cell death
after 24 hours, as indicated by Live-Dead cell staining. PHOU nanoparticles with
a size of a ~202 nm and a zeta potential of ~2.7 mV, as established using a Zetasizer
Nano, were successfully prepared by nanoprecipitation. Ultimately, consistent
nanoparticle development through single emulsion using PHOU was unsuccessful
so a miniemulsion technique was used for following nanoparticle development.
After achieving consistent nanoparticle development through double emulsion,
folate groups were to be attached to the nanoparticles to specifically target cancer
cells, but due to polymer cross-linking occurring through that attachment process
that prevented successful folate attachment, nanoparticle development with new
PHA polymers was necessary. PHO-N3 was successfully used to develop
nanoparticles through mini-emulsion, a shorter and more efficient process than
previous development methods. Through the use of a Zetasizer Nano, the size and
zeta potential for the PHO-N3 nanoparticles were established as ~108 nm and -80
mV; suitable values for drug delivery. Although further assessment is required to
establish the cytoxicity of the nanoparticles, the results provide preliminary
evidence that nanoparticles of an appropriate size for drug delivery can be prepared.
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Executive Summary
A successful cell cycle requires a large number of signals to initiate
cellular activities when necessary, end the cellular activities when appropriate,
prevent unregulated cell division, and check that all cellular activities are running
properly. Any cell that does not meet those constraints is considered diseased,
such as cancer. Cancer is characterized by uncontrolled cell growth and the
potential to metastasize or invade adjacent tissue. Because of these mutations,
cancer is a challenging disease to treat, an issue illustrated by mortality rates.
According to the Center for Disease Control and Prevention, cancer is the
second leading cause of death in United States. In 2013 alone, there were 580,350
reported deaths as a result of cancer as well as 1,660,290 new cases according to
the statistics released by the American Cancer Society. These statistics reaffirm
the need for continuous study of novel cancer treatment methods.
Current treatment strategies for cancer are focused on the removal or
destruction of diseased tissue often through means of radiation and chemotherapy.
These treatment options are accompanied by a significant level of toxicity which
has great potential to further medical issues in the afflicted patient. Nanomedicine
has become a frequent topic of discussion with regard to cancer therapeutics.
Utilizing cancer drug delivery systems such as liposomes, micelles, or
nanoparticles  can  increase  an  encapsulated  drug’s  circulatory  stability  thereby  
increasing the probability of the drug arriving at the diseased tissue. Molecules
that target specific receptors on the tumorous tissue can be attached to polymers
called polyhydroxyalkanoates (PHAs) in order to enhance specific targeting of the
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diseased tissue and increase efficacy of the drug. The combination of circulatory
stability and targeting results in increased efficacy and reduced toxicity.
Although there has been success in the use of nanocarriers for treatments,
application of this in a clinical setting is difficult due to the lack of
biodegradability and biocompatability. In addition, preparation of current drug
delivery systems is difficult as well as modifying the systems to express desired
properties.
The long-term goal of this project is to develop a modifiable drug delivery
system to treat cancer based on bacteria-produced, environmentally-friendly
polymers [polyhydroxyalkanoates (PHAs)] with high biodegradability and
inherent biocompatibility. The objective is to create a PHA-based carrier system
that can be easily modified to incorporate a targeting molecule, in this case folate,
that improves selectivity for cancer tissue and that is effective at encapsulating
and improving the efficacy of an existing anti-cancer drug, paclitaxel (PTX). My
hypothesis is that environmentally-friendly, cancer-targeted, PHA nanoparticles
can be prepared with ease and that these particles can be used to enhance the
therapeutic efficacy of encapsulated PTX. My hypothesis will be tested by
pursuing the following specific aims: (1) synthesize and characterize PHA and
PHA-folate (PHAF) nanoparticles and (2) establish the therapeutic efficacy of
PTX-loaded PHA and PHAF nanoparticles.
The respective anticipated results are: (1) biocompatible, cancer-targeted
nanoparticles can be prepared from PHA and PHAF; and (2) the therapeutic
efficacy of PTX can be enhanced through incorporation into PHA and PHAF
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nanoparticles. Also, PTX loaded into actively targeted, PHAF nanoparticles is
anticipated to be more effective than if loaded into PHA nanoparticles.
The proposed research provides the foundation for the development of a
new, effective cancer treatment strategy based on the use of environmentallyfriendly, bacteria produced polymers than can be easily modified to incorporate a
variety of therapeutics and target many cancer types.
The materials of interest is from a class of biopolymers called
polyhydroxyalkanoates (PHAs). PHAs are synthesized and stored by an
engineered form of E. coli and have received significant attention for industrial
and biomedical applications. The preliminary steps, verifying that the PHA is a
suitable polymer for cancer drug delivery and nanoparticle development, have
been completed.
The goal of the project is to develop an effective PHA-based drug carrier
system characterized by high biodegradability and biocompatibility that can
encapsulate an existing anti-cancer drug called paclitaxel and be modified by
adding a folate molecule in order to target cancer tissue. In order to do this, the
current process for developing PHA nanoparticles has been optimized. After
failing to achieve consistant nanoparticle development through nanoprecipitation
and double emulsion techniques, a miniemulsion technique was found to produce
consistent PHA nanoparticles and was optimized for nanoparticle development.

Previous research in the Nomura Laboratory at SUNY ESF using
engineered E. Coli to produce PHA copolymers was extended beyond saturated
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fatty acids to include 10-undecenoic, 10-undecynoic acid, and 10-azidodeanoic
acid monomers.The method currently being used to develop nanoparticles is a
miniemulsion technique dissolving these PHA copolymers in chloroform and
adding the polymer-chloroform solution to a separate aqueous SDS solution. The
mixture is stirred then ultrasonicated and then stirred again to evaporate off excess
chloroform. By varying the amount of each component used, the nanoparticles
can be optimized to the proper size and surface charge ideal for delivery and
cellular uptake.
In order to assess cellular uptake of nanoparticles, a competitive binding
assay was conducted by incubating lung carcinoma cells with fluorescentlytagged nanoparticles and then viewing them by microscopy using a Zeiss
Axiovert 40 CFL microscope. Due to overlyconfluent cells and the presence of
folates in the media used, uptake was difficult to correctly assess, although it was
observed.
Nanoparticles prepared with PHA copolymers that included terminal
alkynes were reacted with an azide containing fluorescent tag via click chemistry.
By attaching azide functional groups to PHA nanoparticles, additional chemistry
can be used to ultimately attach the folate groups needed for targeting cancer
cells.
In addition, the efficacy of the drug delivery system is being evaluated in
vitro via a WST-8 cell proliferation assay. The anti-cancer effect of PHA-N3
nanoparticles, PHA nanoparticles, PHA nanoparticles with a folate attached
[PHAF], free PTX, PTX-loaded, PHA nanoparticles, PTX-loaded, PHAF
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nanoparticles will be determined using this assay. Currently, anticipated toxicity
has been experienced in PHA-N3 nanoparticles due to the interactions the azide
functional groups have with the cells. Other test materials are currently
undergoing experiment planning or testing for cytotoxicity,
Following the optimization of the nanoparticle development method, PTX
will be encapsulated into the PHA nanoparticles and assessed to determine the
drug encapsulation efficiency. The amount of drug left in the supernatant liquid
remaining after the nanoparticles are developed will be determined using high
performance liquid chromatography. Using this value, the loading capacity (mass
of PTX/mass of nanoparticle) and loading efficiency (percentage of PTX loaded
into nanoparticle/amount added to polymer solution) can be calculated.
Overall the purpose of this study is to synthesize and characterize PHA
and PHAF nanoparticles as well as establish the therapeutic efficacy of drugloaded PHA and PHAF nanoparticles. The knowledge gained from this study is
essential for the development of targeted, environmentally friendly, biopolymerbased drug delivery systems as a method of cancer therapy characterized by
increased  efficacy  and  reduced  toxicity.  In  addition  to  this  study’s  significance  
with respect to cancer treatment, the overall reach extends to treatment methods
for  other  diseases  due  to  the  drug  carrier  system’s  ease  of  manipulation.
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Chapter 1: Introduction
Current treatment strategies for cancer often employ a combination of
established methods to achieve the greatest anti-cancer effect. While these
methods are effective at destroying cancer cells, they are often accompanied by a
significant amount of toxicity. Polyhydroxyalkanoates (PHAs) are a class of
biodegradable biopolyesters produced and stored by bacteria that have received
significant attention for industrial biomedical applications. The number of carbon
atoms in the individual PHA monomers is the greatest determinant of a PHA
polymer’s  physical  properties.  These  PHA  monomers  are  incorporated  by  
bacterial enzymes into polymer chains (figure 1). PHA polymers can either be of
short-chain-length (SCL) with 3 – 5 carbons or medium-chain-length (MCL) with
6 – 14 carbons1,2. PHA copolymers have proven to have material properties
similar to polyethylene and polypropylene and are of special interest for their
biocompatibility1,2. Currently, PHAs have been used in biomedical applications
such as sutures, screws, surgical mesh, stents3, and drug delivery4-10 and this study
aims to expand their role in drug delivery.
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PHA Production by Engineering E.Coli Bacteria

Figure 1. Production of PHA Monomers by Engineering E. coli Engineered E. coli can
produce PHA copolymers from fatty acids with defined repeating unit compositions and material
properties.1

PHAs were originally found present in bacteria in the 1920s11 and since
then, the process has been adapted for the laboratory environment. As shown in
figure 2, bacteria are fed fatty acids of varying chain lengths to produce PHA
monomers of different sizes. In fermentation chambers, PHAs are developed
within the bacteria, which are then lysed for retrieval and purification of the PHA.
The resulting product is a bioplastic with material properties largely determined
by the monomer composition of the PHA. One such property, biodegradability, is
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inherent of all PHA polymers and an important characteristic of environmentallyfriendly plastics.
Polyhydroxyalkanoates in Biomaterials

Figure 2. Life Cycle of PHA Polymers in Biomaterials. PHAs are produced within bacteria in
both nature and the laboratory environment. The polymer is retrieved and purified and the
resulting bioplastic is used for biomaterial applications. Ultimately, the polymer is biodegradable
and breaks down back into the environment where it is nontoxic.

The Nomura Research Group at SUNY ESF engineered a strain of
Escherichia coli to produce PHA polymers with specifically defined repeating
chains from fatty acids12,13. Having the ability to produce consistent repeating
polymer composition allows for the development of PHA polymers with desired
material properties. Additionally, functionalized PHAs can be modified through
thiol-ene and copper-catalyzed click chemistry to attach fluorescent tags or folate
groups to visualize uptake by the cells or specifically target cancer12.
Nanoparticles designated for drug delivery applications, like the ones used in this
study, require polymers with biodegradable or biocompatible properties, such as
PHA.
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Polymer nanoparticles can be developed through a variety of methods15,
but the two main methods used in this study were nanoprecipitation and
miniemulsification. Nanoprecipitation, a solvent displacement method, involves
dissolving the polymer from which you wish to make nanoparticles in an organic
solvent, before slowly adding the organic solution to an aqueous solution of nonsolvent with surfactant. The nanoparticles are produced when the polymer solvent
quickly diffuses in the non-solvent phase as drops of the organic solution are
added. The tension between the solvent and non-solvent phases decreases when
the two phases are mixed so the nanoparticle surface area increases and
nanoparticles precipitate out. Miniemulsification involves dissolving the polymer
in an organic solvent and mixing it with a solution of water and a surfactant. The
mixture is then subjected to high shear through ultrasonication to produce the
emulsified nanoparticles. The organic solvent is removed by heating the solution
to evaporate the solvent out. Anti-cancer drugs such as paclitaxel21-24 can be
incorporated into the nanoparticles simply by dissolving the drug along with the
polymer in the first step of the nanoparticle development process.
One of the greatest challenges of cancer treatment is tempering the anticancer  effect  of  the  treatments  used  such  that  healthy  cells  aren’t  damaged.  One  
solution to this is to develop nontoxic treatment methods and ensure that only the
diseased site is effected. Using a family of chemical reactions referred to as click
chemistry, targeting groups and other functional moieties can be directly attached
to PHA polymers that contain functional groups18,19, before or after nanparticle
development. Breast  cancer,  for  example,  overexpresses  folate  receptor  α  so  by  
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attaching folate groups to PHA nanoparticles, breast cancer tissue can be
specifically targeted16,17. Since PHA nanoparticles are biocompatible and
biodegradable, toxicity is limited as paclitaxel is housed within the PHA
nanoparticle, protecting healthy cells as the drugs move through the body.
Furthermore, the addition of folate groups increases the anti-cancer drug
concentration at the diseased tissue rather than healthy tissue.
Brain cancer, on the other hand, is significantly more difficult to treat due
to the presence of the blood-brain barrier preventing the transportation of
necessary anti-cancer drugs to the diseased site. Penetration and transportation
across the blood-brain barrier using drug-loaded carrier systems can be facilitated
and enhanced by using multi-function PHA nanoparticles25 coated with lactoferrin
and transferrin, receptors overexpressed by brain endothelial cells 26.
Additionally, by using certain surfactants in the nanoparticles development
process, the absorption of apolipoprotein A-1 in the blood by the nanoparticles
can be encouraged, further enhancing blood-brain barrier transport27. Finally, antiepidermal growth factor antibodies and angiopep-2 ligands can be attached to
PHA nanoparticles for additional blood-brain barrier transport enhancement and
the specific targeting of brain cancer due to the overexpression of angiopep-2
ligand receptors in glioblastoma cells28-33. Ultimately, the result is a nontoxic,
environmentally-friendly, targeted drug delivery system.
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Chapter 2: Materials and Methods
The first step in this study was to establish the cytotoxicity of PHA
polymers themselves before nanoparticles development. Indirect contact assays
were used to determine whether elutions of the polymer in cell culture media are
toxic to the cells. For this assay, PHOU was the PHA polymer used along with
lung cancer cells of A549 cell line which uses F-12K media with 10% fetal
bovine serum (FBS). Cells were cultured in four wells of a 24-well culture plate
and incubated for 24 hours. The polymer was sterilized by submerging it a 70%
ethanol solution for 30 minutes and then dried on a hot plate so that the ethanol
was no longer present. After drying, the polymer was submerged in 15 mL of the
culture medium and incubated for 24 hours at 37oC. After 24 hours, the culture
media was removed from the wells of the well plate and replaced with elutions of
the polymer-contaminated media for two of the wells, and non-contaminated
media for the other two wells. The cells in the well-plate were incubated again for
24 hours.
The indirect contact assay (figure 3) was performed using green (for live
cells) and red (for dead cells) fluorescent dyes from the Life Technologies
Live/Dead Assay which included calcein AM and ethidium homodimer-1. A
Live/Dead  stain  solution  was  made  from  the  two  dyes  along  with  Dulbecco’s  
phosphate-buffered saline (D-PBS). The media was removed and replaced with
Live/Dead stain for each well. After incubating the cells again for 45 minutes, the
Live/Dead stain was removed and cells were rinsed with D-PBS. Using
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fluorescence microscopy, images of live and dead cells can be obtained with
green cells representing healthy cells and red cells representing dead cells.
Indirect Contact Assay

(a)

(b)

(d)

(e)

(c)

(f)

Figure 3. Indirect Contact Assay for PHA and A549 Lung Carcinoma Cells (a) Sterilization of
polymer in 70% EtOH for 24 hours (b) Drying PHA to remove EtOH (c) Addition of PHAcontaminated media elutions to two wells of A549 lung carcinoma cells. Incubate 24 hours at 37 oC. (d)
Two wells of cells containing PHA-contaminated media and two wells containing uncontaminated
media. Incubate 24 hours at 37oC (e) Media from all wells replaced with Live/Dead Stain. Incubate 45
minutes at 37oC. (f) Observe live and dead cells with fluorescence microscopy

The next step was to conduct a direct contact assay (figure 4) to determine
whether cytotoxicity was experienced for cells cultured directly on PHA. The
polymer was initially sterilized in the same manner as in the indirect contact assay
and then adhered to the bottom of a 6 well plate. Cells of A549 lung carcinoma
cell line were cultured on top of the polymer and incubated for 24 hours at 37oC.
After 24 hours, the media was removed and the same Live/Dead stain from the
indirect contact assay was added. The cells were again incubated at 37 oC for 45
minutes and then rinsed with D-PBS. The polymer was carefully removed from
the well plate with sterilized tweezers and placed on a glass slide for observation
using fluorescence microscopy.
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Direct Contact Assay

(a)

(b)

(e)

(c)

(f)

(d)

(g)

Figure 4. Direct Contact Assay for PHA and A549 Lung Carcinoma Cells (a) Sterilization of
polymer in 70% EtOH for 24 hours (b) Drying PHA to remove EtOH (c) Adherence of PHA to well
of 6-well plate (d) Cells cultured on PHA in well. Incubate for 24 hours at 37 oC (e) Media replaced
with Live/Dead Stain. Incubate 45 minutes at 37oC. (f) PHA placed on glass slide for microscopy (g)
Observe live and dead cells with fluorescence microscopy

After establishing PHA cytotoxity, successful nanoparticle development
was the next step of the study. Intially, PHA nanoparticles were developed using a
solvent displacement method known as nanoprecipitation (figure 5). PHOU was
dissolved in acetone and then added dropwise to aqueous solution (PBS/Pluronic
F-68 or Water/Pluronic F-68 was used). The mixture was stirred for 24 hours at
room temperature at 1200 rpm using a stir bar and magnetic stir plate to allow the
acetone to evaporate out. After 24 hours, the mixture was filtered using a 0.45
micron nylon filter and then ultracentrifuged for 1 hour at 51354 x G and 4oC.
The supernatant was discarded and the nanoparticles were resuspended in 9 mL
deionized water for additional rinsing by centrifuging again under the same
conditions. Following the second centrifugation, the supernatant was discarded
and the nanoparticles were resuspended in 3 mL of deionized water.
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Nanoparticle Development: Nanoprecipitation

Centrifugation
& Filtration

Solvent Evaporation

(a)

(b)

(c)

Figure 5. Nanoparticle Development through Nanoprecipitation Method. (a) Organic Phase
added drop-wise to aqueous phase (b) Polymeric Nanoparticles suspended in Aqueous Phase (c)
Polymeric Nanoparticles suspended in deionized water

Ultimately, due to inconsistencies with the nanoparticles developed
through the nanoprecipitation method, other methods of nanoparticle development
had to be explored. Using the miniemulsion method shown in figure 6, 60 mg of
PHA polymer was dissolved in 1.0 mL of chloroform which was then added to
2.73 mL aqueous sodium dodecyl sulfate (SDS) (4.44 mg/mL). The mixture was
then stirred at room temperature for an hour on a magnetic stir plate resulting in
monodisperse chloroform droplets containing the dissolved polymer, separated
from water by the SDS. Ultrasonication was then used (40% amplitude, 4 second
pulse, 1 minute) to emulsify the droplets and form the PHA nanoparticles.
Chloroform is then removed by heating the emulsion at 70 oC for 2 hours, leaving
the PHA nanoparticles suspended in water.
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Nanoparticle Development: Miniemulsion

(a)

(b)

(c)

(d)

(e)

Figure 6. Nanoparticle Development through Miniemulsions. (a) PHA polymer dissolved in
Chloroform added to aqueous SDS (b) Pre-emulsification: Mixture stirred at RT for 1 hour (c)
Ultrasonication: Mixture emsulsified forming PHA nanoparticles (d) Emulsion heated for 2 hours
at 70oC to remove chloroform (e) PHA nanoparticles dissolved in water

Following nanoparticle development, it was necessary to characterize the
nanoparticles. This was done by quantitatively measuring size and zeta potential
(the surface electric charge of the nanoparticle) through dynamic light scattering
using a Zetasizer Nano device. Atomic force microscopy and scanning electron
microscopy was used to observe the shape of the nanoparticle and confirm the
size.
Once the nanoparticles were found to be of appropriate size and zeta
potential for drug delivery applications, functional groups were attached using
click chemistry. Fluorescent tags were attached to PHA nanoparticles and then
added to the media used to culture breast cancer cells of the MT3 cell line (figure
7). After incubating the cells with the PHA nanoparticle-contaminated media for
24 hours at 37oC, fluorescent microscopy was used to observe the PHA
nanoparticles with the cells.
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Click Reaction of Functionalized Nanoparticles

(a)

(b)

(c)

Figure 7. Copper Catalized Click Reaction to produce Fluorescently-Tagged Nanoparticles.
(a) Red fluorescent tag (b) Alkyne-modified PHA nanoparticles (c) Fluorescently-tagged PHA
nanoparticles

Another step after nanoparticle development is to establish the
cytotoxicity of the nanoparticles themselves. Using a WST-8 assay depicted in
figure 9, nanoparticle cytotoxicity can be determined based on the metabolic
activity of the cells. Lung or breast cancer cells were cultured in two rows of 7
wells in a 96-well plate and incubated for 24 hours at 37oC. A dilution series
(figure 8) was made by adding 200 µL of PHA nanoparticle solution to 800 µL of
cell culture media in a 1.5 mL microcentrifuge tube. 500 µL of cell culture media
was added to 5 additional 1.5 mL microcentrifuge tubes as well. After mixing the
PHA nanoparticle solution in media well, 500 µL was removed and mixed with
the edia of the next tube in succession. This process was repeated until the final
tube contained 1000 µL total volume.
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Dilution Series

Figure 8. Dilution Series of PHA Nanoparticles in Cell Culture Media. The volume labels
beneath the graphics depict initial microcentrifuge tube contents and volume labels within the red
lines show the movement of the PHA nanoparticles and nanoparticle/media mixture through the
dilution. The result is 6 tubes containing an exact fraction of the initial nanoparticle. For each
tube, the concentration compared to the original nanoparticle solution respectively is (1) 1/5 (2)
1/10 (3) 1/20 (4) 1/40 (5) 1/80 (6) 1/160

The dilution series was added in 200 µL aliquots to each respectively
numbered experimental well of the 96-well plate. The 7th well of each row is the
control well and media was replaced with 200 µL of normal culture media. The
8th well was designated as a blank well and remained on touched as this point.
The cells were then incubated again for 24 hours at 37oC. After 24 hours, the
media and nanoparticles within each well were removed and replaced with 100
µL of media and 10 µL of CCK-8  reagent  from  Dojindo’s  Cell  Counting  Kit-8.
After incubating once more for 1 hour, absorbance values were obtained using a
plate reader and a wavelength of 450 nm.
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WST-8 Assay

1
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C

B
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5

6
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(a)

(b)

(c)

(d)

Figure 9. WST-8 Assay for PHA Nanoparticles and Cancer Cells. (a) Cells cultured in two
rows of 7 wells each and incubated for 24 hours at 37 oC (b) Dilution series added to experimental
wells and media replaced in control well (c) 10 µL of CCK-8 reagent and 100 µL culture media
added to each well including blank well. Incubate 1 hour at 37 oC (d) Obtain absorbance values
using plate reader at 450 nm wavelength

14
Chapter 3: Results
The polymer, poly(3-hydroxy-octanoate-co-10-undecanoate) (PHOU),
was shown to be nontoxic to the A549 cell line through the indirect contact assay.
Live and dead cells are indicated by green and red fluorescence, respectively. This
is as a result of the components used to develop the Live/Dead stain. Calcein AM,
for example, is well retained in live cells, and produces green fluorescence in
those cells. Ethidium homodimer-1, however, associates with damaged cell
membranes that are present in dead cells and fluoresces with the nucleic acids that
are no longer protected by the damaged cell membranes. As a result of these dyes
and their associated reactions, only live cells can be depicted as green and only
dead cells can show red. As seen in figure 10, lung cancer cells of the A549 cell
line fluoresce green and no red fluorescence is observed, signifying a lack of
cytotoxicity through indirect contact.
Indirect Contact Assay Results

Control

PHOU

Figure 10. Live/Dead Assay for PHOU and A549 lung carcinoma cells. Indirect contact assays
were conducted with live/dead staining and fluorescence microscopy was used to show that
elution tests did not result in any changes in cellular appearance or proliferation after incubation
for 24 hours at 37oC.

PHOU was shown to result in cell death for the A549 cell line through the
direct contact assay. Since the stain used for this assay is the same as the indirect
contact assay, resulting pictures from fluorescence microscopy can be analyzed in
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the same manner. As seen in figure 11, lung cancer cells of the A549 cell line
fluoresce red with very little green fluorescence present, signifying severe cell
death.
Direct Contact Assay Results

Control

PHOU

Figure 11. Direct Contact Assay for PHOU and A549 Lung Carcinoma Cells. Cells were
cultured directly on PHOU. Direct contact assays were conducted with Live-Dead staining.
Fluorescent microscopy was used to show severe death after incubation at 37 oC for 24 hours.

Nanoparticles were characterized by their size and zeta potential using a
Zetasizer Nano. The Zetasizer Nano uses dynamic light scattering to determine
particle size. By shining a monochromatic light source through a clear solution of
dissolved particles, the resulting light intensity patterns are captured by a
photoreceptor and can be correlated to particle size which is calculated and
displayed along with the size profile of the particle by a computer and
accompanying software. The Zetasizer Nano measures the Brownian motion of
the particles through dynamic light scattering and uses the Stokes-Einstein
equation to relate the motion of the particles to particle size. For nanoparticles to
be suitable for drug delivery applications, they must ideally must be 100 nm in
diameter (size) and have an absolute zeta potential value greater than 30 mV (real
zeta potential value >30mV or <-30 mV). Nanoparticles were successfully
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developed using the nanoprecipitation method, but consistent sizes and ideal zeta
potential values were unable to be achieved as shown in table 1.

PHOU Nanoparticle Characterization: Size and Zeta Potential

PHOU Acetone
(mg)
(mL)

Pluronic F-68 PBS Water Average
(wt% )
(mL) (mL) Size (nm)

25.0

5.0

4.0

15.0

0.0

248.70

Zeta
Potential
(mV)
-15.30

PDI

9.0

3.0

4.0

10.0

0.0

186.75

-1.83

0.2495

9.0

3.0

5.0

10.0

0.0

175.40

-19.00

0.2510

9.0

3.0

10.0

10.0

0.0

256.65

-25.50

0.0870

15.0

3.0

10.0

10.0

0.0

306.40

-4.560

0.1050

9.0

3.0

1.0

0.0

10.0

143.39

-19.23

0.0287

9.0

3.0

10.0

0.0

10.0

194.27

-12.82

0.0295

9.0

9.0

0.1

0.0

10.0

90.51

-10.17

0.1022

9.0

9.0

0.5

0.0

10.0

46.43

-7.53

0.4353

9.0

9.0

1.0

0.0

10.0

142.02

-19.77

0.0317

9.0

9.0

10.0

0.0

10.0

109.30

-11.90

0.0560

0.2523

Table 1. Size and Zeta Potential Measurements for PHOU Nanoparticles Developed
Through Nanoprecipitation. After a variety of attempts at nanoparticle development through
nanoprecipitation with size and zeta potential ideal for drug delivery (~100 nm; >30 mV or < 30mV), consistent and appropriately sized and charged nanoparticles were not achieved.

Atomic Force Microscopy (AFM) was used to confirm the presence of
PHOU nanoparticles and verify the relative size (Figure 12). A small glass slide
the size of a penny was prepared for AFM by placing a 10 µL drop of PHOU
nanoparticle solution on the slide and allowing the water to evaporate, leaving
PHOU nanoparticles dried on the slide. The nanoparticles were observed using an
atomic force microscope which develops a picture of the material on the AFM
slide through the force response of a needle interacting with the test material. A
scale can be used to associate the diameter of the particles in the pictures to the
real particle size.
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AFM Images of PHOU Nanoparticles

Figure 12. Atomic Force Microscopy Images of PHOU Nanoparticle Developed Through
Nanoprecipitation. The presence of PHOU nanoparticles was confirmed and relative size verified
by AFM.

Scanning Electron Microscopy was also used to observe the shape and
confirm the presence of PHOU nanoparticles. PHOU nanoparticles were freezedried and prepared on SEM sample holders and then observed using a scanning
electron microscope. As shown in figure 13, SEM images of PHOU nanoparticles
confirm inconsistent nanoparticle development.
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SEM Images of PHOU Nanoparticles

(a)

(b)
Figure 13. Scanning Electron Microscope Images of PHOU Nanoparticles Developed
Through Nanoprecipitation. SEM confirms inconsistent nanoparticle development with PHOU
nanoparticles developed through nanoprecipitation. (a) The spherical shape of the nanoparticles
shows nanoparticle development however agglomeration suggests the freeze-drying procedure
could be improved. (b) The unrecognizable shape suggests that the formation cannot sustain its
shape and therefore is not ideal for drug delivery.

After PHOU nanoparticles developed through nanoprecipitation proved to
be too inconsistent for drug delivery applications, a new method was used called
miniemulsion that successfully achieved consistent nanoparticle development
with nanoparticles of appropriate size and zeta potential for drug delivery. PHA
nanoparticles developed using miniemulsions used the PHA polymer, PHO-N3,
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an azide-terminated PHA. These nanoparticles were measured using a Zetasizer
Nano in the same manner as the previous nanoparticles. As shown in Table 2,
PHO-N3 nanoparticles developed through miniemulsions achieved sizes and zeta
potentials ideal for drug delivery.
PHO-N3 Nanoparticle Characterization: Size and Zeta Potential
PHO-N3
(mg)

Chloroform
(mL)

Aqueous SDS (mL)
[4.44 mg/mL]

Average Size
(nm)

Average Zeta
Potential (mV)

PDI

60.0

1.0

2.73

103.4

-79.53

0.0477

Table 2. Size and Zeta Potential Measurements for PHO-N3 Nanoparticles Developed
Through Miniemulsions. Consistent PHO-N3 nanoparticles of appropriate size and zeta potential
for drug delivery were achieved and measured using a Zetasizer Nano.

Functional group-modified PHA nanoparticles were developed using a
several different functional groups through miniemulsion with low polydispersity
and appropriate  size  for  drug  delivery  applications  (table  3).  Although  it’s  not  
shown, zeta potential for each functionalized nanoparticle was found to be around
-70 mV which is consistent with the charge of the SDS incorporated in the
nanoparticle solution.
Functionalized PHA Nanoparticle Characteristics

Polymer
PHO

Functional Group
Alkene
Alkyne
Azide:Alkyne (1:1)

Size (nm)
88.4
136.8
133.5

PDI
0.09
0.09
0.016

Table 3. Size and Zeta Potential of Functionalized PHA Nanoparticles. Successful
development of functionalized PHA nanoparticles was achieved with low polydispersity and
suitable sizes for drug delivery applications.

As a demonstration of the ability to perform click reactions on
functionalized nanoparticles, fluorescent tags were attached (figure 5) and cellular
uptake was observed. Figure 14 depicts red, fluorescently tagged, alkyne modified
PHA nanoparticles within breast cancer cells of the MT3 cell line.
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Cellular Uptake of Functionalized PHA Nanoparticles

Figure 14. Cellular Uptake of Fluorescently Tagged PHA Nanoparticles by Breast Cancer
cells. Alkyne-modified PHA nanoparticles, fluorescently-tagged through click chemistry were
observed within breast cancer cells of the MT3 cell line using fluorescence microscopy

Nanoparticle measurements were taken again 3 days after initial
nanoparticle development to assess stability. Zetasizer Nano results show
comparable results for size and zeta potential for both periods (figure 15).
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Size and Zeta Potential: 24 and 72 Hours

(a)

(b)
Figure 15. Size and Zeta Potential of PHO-N3 Nanoparticles at 24 and 72 hours. Size and
zeta potential remain consistent (a) Size and zeta potential at 24 hours (b) size and zeta potential
at 72 hours
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After successful nanoparticle development through miniemulsions, the
cytotoxicity of the functionalized nanoparticles needed to be established. Initial
WST-8 assays resulted in an IC50 curve (figure 16) that allowed us to determine
the concentration at which 50% of cell death is observed, or the IC50
concentration. For PHO-N3 nanoparticles, the IC50 concentration value was
found to be 2.6815 mg/mL. From additional WST-8 assay results, no cytotoxicity
of was shown for PHO-N3 nanoparticles toward the MDA-MB-231 breast cancer
cell line despite increasing concentration (figure 17).
IC50 Curve for PHA Nanoparticles

Figure 16. IC50 Curve for PHO-N3 Nanoparticles and MDA-MB-231 Breast Cancer Cells.
Based on the absorbance values from a WST-8 Assay assessing the cytotoxicity of PHO-N3
nanoparticles and MDA-MB-231 cells, an IC50 curve was established and an IC50 value of
2.6815 mg/mL was obtained. IC50 represents the concentration at which 50% of cell death
occurs. On y axis, 1 represents no cytotoxicity and 0 represents total cell death. Values above 0.8
are considered nontoxic.
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WST-8 Assay Results

1.2

Relative Absorbance

1
0.8
0.6
0.4
0.2

0
0.000 0.045 0.091 0.181 0.363 0.725 1.450
Concentration (mg/mL)

(a)

(b)
Figure 17. WST-8 Assay Results for PHO-N3 Nanoparticles and MDA-MB-231 Cell Line.
PHO-N3 nanoparticles have shown no cytotoxicity (absorbance < 0.8) with increasing
concentration compared to widely-accepted PLGA nanoparticles.
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Chapter 4: Discussion
While cells of the A549 cell line experienced no cytotoxicity through the
indirect contact assay, cell death was observed when the cells were cultured
directly on top of the PHOU polymer. This is believed to be as a result of the
presence of bacterial microbes present within the folds of the polymer which
protected the microbes from removal when the polymer was purified before the
assay. The presence of toxic components within the polymer as well as crosslinking within the polymer structure and in general a lack of consistency among
results for PHOU nanoparticles prompted nanoparticle development using another
PHA, polyhydroxyoctanoate (PHO).
Although the material itself is partially responsible for the inconsistent
nanoparticle development, the process of nanoprecipitation itself was found to be
an inconsistent method altogether. Through nanoprecipitation, a wide range of
sizes were produced even among nanoparticles developed identically. Zeta
potential values were inconsistent and did not fall within the suitable range for
drug delivery applications. The miniemulsion process, however, was not only an
effective method for consistent nanoparticle development that produced
appropriately sized and charged particles for drug delivery, but also a more
efficient method.
The miniemulsion process requires a max development time of 4 hours
from preparation through chloroform removal compared to the 28 plus hours
required for nanoprecipitation. Steps for nanoprecipitation, such as centrifugation
was the primary inconsistent element of the nanoparticle development process
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since high speeds were required to separate out the nanoparticles. Often, the
resulting nanoparticle pellet would quickly begin dissolving back into the
supernatant after centrifugation, resulting in loss and ocacasionally negating the
centrifugation step altogether. Monodisperse chloroform droplets containing
dissolved PHA, separated from water by SDS are readily made in the
miniemulsion process due to the kinetic behavior of the reagents involved and
then a high shear energy source (in this case ultrasonication) is used to complete
the emulsion and form the nanoparticles. At this point the nanoparticle solution
can be purified simply by boiling out the chloroform. The result was a more
consistent, ideally characterized nanoparticle carrier system than that developed
by nanoprecipitation.
With regards to the cellular uptake of the fluorescently-tagged PHA
nanoparticles, initial challenges were presented as a result of the presence of
folates in the culture media used for the cells. Since breast cancer cells
overexpress folate receptors, folate groups are an ideal targeting group for
nanoparticle carrying drugs intended to treat breast cancer. However due to the
presence of folates in the fetal bovine serum component of the culture medium,
the presence of folate-functionalized nanoparticles within the breast cancer cells
was not as pronounced.
The WST-8 assays provided some challenges as well. Initially, the assay
was conducted successfully resulting in an IC50 curve and the establishment of an
IC50 value (figure 16). Following attemps, however, resulted in unusable results
in which absorbance values for experimental wells were found to be greater than
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that of the control well. One potential cause of the unusual absorbance values
found for experimental wells was the presence of nanoparticles within the wells
during analysis with a plate reader. The media containing the test material for
WST-8 assays is supposed to be removed before the addition of the CCK-8
reagent, however wells were inadequently rinsed, resulting in the presence of
nanoparticles within the wells still during plate reading. The presence of
nanoparticles skewed the absorbance values determined by the plate reader
implying that cell proliferation was greater for experimental wells than in the
control wells. Additional assays were performed with adequate removal of PHA
nanoparticles and usuable result were obtained again that displayed no
cytotoxicity (figure 17). Normally, azide would be toxic to cells but by
conjugating the azide to form PHO-N3, cytotoxicity is eliminated.
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Chapter 5: Conclusion and Future Work
Consistent development of PHA nanoparticles with size and zeta potential
suitable for drug delivery was achieved. Despite initial concerns regarding PHA
cytotoxicity, functionalized PHA nanoparticles were found to display no
cytotoxicity to MDA-MB-231 breast cancer cells. Highly efficient click chemistry
reactions were used to successfully attach functional groups to PHA
nanoparticles. Through click chemistry, fluorescent tags were attached to alkynemodified PHA nanoparticles and fluorescence microscopy was used to observe
cellular uptake of these functionalized nanoparticles by the MT3 breast cancer
cell line. While further work is needed to assess the drug-loading efficiency,
stability, perform differential scanning calorimetry, and further establish PHA
nanoparticle cytotoxicity, this study has shown that functionalized PHA
nanoparticles with applications in targeted drug delivery can be developed.
Further work must be done to assess the stability of the PHA
nanoparticles. By taking size and zeta potential measurements of PHA
nanoparticles daily for a week and then once a week for a 3 months, size and zeta
potential stability can be assessed. Thermal stability and material characteristics
of the PHA nanoparticles can be established through differential scanning
calorimetry. A thermal analyzer called a differential scanning calorimeter is used
to determine material properties such as glass transition temperature and melting
point. By knowing the thermal properties of the PHA nanoparticles,
determinations can be made regarding the stability of the nanoparticles under a
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variety of conditions. The most of relevant of which being the biological
conditions found present in the human body.
Anti-cancer drugs such as PTX can be loaded within the PHA
nanoparticles by dissolving the drug simulataneously with the polymer in
chloroform when developing the nanoparticles through miniemulsions. The
amount of drug left in the supernatant liquid remaining after the nanoparticles are
developed will be determined using high performance liquid chromatography.
Using this value, the loading capacity (mass of PTX/mass of nanoparticle) and
loading efficiency (percentage of PTX loaded into nanoparticle/amount added to
polymer solution) can be calculated.
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